Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Pricing Strategies Generic Drugs

Lamotrigine Leads October Increases In UK

Pricewatch UK – October 2023

  • Data

Executive Summary

Four presentations of epilepsy treatment lamotrigine topped WaveData’s table of the fastest-rising prices of typical generics in the UK in October.

You may also be interested in...



Fresenius And Formycon File Ustekinumab In US

Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.

Sandoz Partner Samsung Bioepis Settles On Stelara In US

Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.

IHP Launches Big Give Campaign For 2023

Running until 5 December, the Big Give campaign run by UK-based charity International Health Partners is once again doubling the value of donations, this year to support its child oncology programs in Malawi and Cameroon.

Table

View full table

Topics

Tags:
Market Intelligence Pricing Strategies Generic Drugs
Latest Headlines

Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Fresenius And Formycon File Ustekinumab In US

What’s Next? Five Things To Look Out For In December

See All
UsernamePublicRestriction

Register

GB153114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By